PHARMACOKINETICS OF RIMONABANT IN FEMALE BABOONS

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 该项目的一个主要目的是研究利莫那班在降低肝脏脂肪方面的效果，利莫那班是一种用于人类减肥的药物，这种疾病被称为NASH，即非酒精性脂肪性肝炎，见于很少饮酒或不饮酒的人。肥胖和糖尿病是人类患NASH的两个最大风险因素。这项先导性研究旨在1)允许随着体重减轻而发生的胰岛素敏感性的变化，2)证明我们执行稳定同位素输注方案的能力，以及3)测量使用利莫那班的NASH患者脂肪(甘油三酯)的相对来源，这些脂肪在脂蛋白中分泌并储存在肝脏中。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A primary aim of this project is to study the effect of Rimonabant, a drug used for weight loss in humans, in reducing liver fat, a condition called NASH, nonalcoholic steatohepatitis, found in individuals who consume little or no alcohol. Obesity and diabetes are the two strongest risk factors for the development of NASH in humans. This pilot study has been designed to 1) allow changes in insulin sensitivity that can occur with weight loss, 2) demonstrate our ability to perform the stable isotope infusion protocols, and 3) measure the relative sources of fats (triglycerides) that are secreted in lipoproteins and stored in the liver in NASH with Rimonabant.